# HIV Vaccines (2023-2025)

> **10 papers on mRNA vaccines, broadly neutralizing antibody induction, and clinical trials.**

---

## Papers in This Section

| ID | Title | Year |
|:---|:------|:-----|
| VAX-001 | mRNA HIV Vaccine Phase 1: Tier 2 Neutralizing Antibodies | 2025 |
| VAX-002 | IAVI G002/G003 Trials: bnAb Pathway Proof-of-Concept | 2025 |
| VAX-003 | NIH HVTN 302: Three mRNA HIV Vaccines | 2024 |
| VAX-004 | Progress and Challenges in HIV-1 Vaccine Research | 2025 |
| VAX-005 | Vaccination Induces bnAb Precursors to HIV gp41 | 2024 |
| VAX-006 | Vaccine Induction of Heterologous HIV-1-Neutralizing Ab Lineages | 2024 |
| VAX-007 | Novel Vaccine Concept for Multiple Types of HIV bnAbs | 2024 |
| VAX-008 | 2024 HIV Vaccines and Passive Immunization Pipeline | 2024 |
| VAX-009 | Germline-Targeting Epitope Scaffold Nanoparticles | 2024 |
| VAX-010 | mRNA Vaccine Urticaria Safety Analysis | 2025 |

---

## Key Themes

1. **mRNA Platform**: Rapid development and strong immunogenicity
2. **bnAb Induction**: Strategies to elicit broadly neutralizing antibodies
3. **Germline Targeting**: Activating rare bnAb precursor B cells
4. **Membrane-Anchored Trimers**: Native-like envelope presentation
5. **Global Trials**: Multi-site international studies

---

*See [00_HIV_PAPERS_INDEX.md](../00_HIV_PAPERS_INDEX.md) for complete index.*
